Latest Headlines

  1. BD Granted FDA 510(k) Clearance For BD FACSLyric™ Flow Cytometer With Newly Integrated BD FACSDuet™ Sample Preparation System 10/5/2020

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ Flow Cytometer with the Integrated BD FACSDuet™ Sample Preparation System

  2. LabCorp COVID-19 Molecular Test Innovation Receives FDA Authorization 10/2/2020

    LabCorp, a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that it is the first commercial laboratory to receive an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new, high-throughput method that uses heat and technology to extract RNA from samples collected for COVID-19 molecular testing

  3. Ocean Tomo Bid-Ask™ Market Portfolio Of U.S. Patents For Time Resolved Spectrometer System And Methods Delivers A Simplified Field Sample Analysis System 10/2/2020

    Ocean Tomo Transactions, LLC will auction a portfolio of 3 U.S. patents directed to novel methods and devices for time-resolved spectroscopy in multiple applications through the Ocean Tomo Bid-Ask™ Market, auction lot 116

  4. Technopath Clinical Diagnostics Introduces The First Unified, Purpose-Built Quality-Control (QC) Platform Providing A Higher Level Of Confidence In The Precision And Accuracy Of Patient Sample Results 10/1/2020

    Technopath, a leading global provider of SaaS-based QC data management solutions and third-party laboratory quality controls, today introduced IAMQC Infinity to support the growing need from modern laboratories for robust management of overall quality control and proficiency testing

  5. PerkinElmer EONIS Screening Test Receives CE-IVD Clearance 10/1/2020

    PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the Company’s EONIS screening assay for newborns that simultaneously tests for SMA (spinal muscular atrophy), SCID (severe combined immunodeficiency) and XLA (X-linked agammaglobulinemia) has received CE-IVD approval

  6. PCR Biosystems Introduces Kit For Reliable Quantification Of Libraries Prepared For Illumina® NGS Systems 9/30/2020

    PCR Biosystems, the UK-based PCR experts, have expanded their range of specialist molecular biology kits with the introduction of NGSBIO Library Quant Kit for Illumina

  7. Applied DNA Signs Master Services Agreement With Stony Brook University Hospital For COVID-19 Diagnostic Assay Kit And Automated Systems, Receives Initial Purchase Order 9/29/2020

    Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced the signing of a Master Services Agreement (MSA) with Stony Brook University Hospital (“SBUH”), the largest academic medical center on Long Island, N.Y.

  8. Cancer Genomic Screening Program LC-SCRUM-Asia Adopts Latest Thermo Fisher Scientific NGS Solutions 9/29/2020

    LC-SCRUM-Asia, a leading cancer genomic screening program, has selected Thermo Fisher Scientific's Ion Torrent Genexus System* and Oncomine Precision Assay*, a pan-cancer panel, to advance precision medicine in Asia

  9. Advanced Instruments Introduces The OsmoTECH® XT Single-Sample Micro-Osmometer 9/29/2020

    Advanced Instruments - an innovative developer of scientific and analytical instruments and related services for the biotech industry—announced the latest release to its biotech instrument portfolio, the OsmoTECH XT Single-Sample Micro-Osmometer

  10. Oxford Immunotec Announces Food And Drug Administration (FDA) Clearance Of The T-SPOT®.TB Test For Use In Pediatrics Over The Age Of Two 9/29/2020

    Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has received clearance from the FDA to amend the pediatric age limitation to allow use of the T-SPOT.TB test in individuals two years of age and older